Related Experiment Video
Updated: May 30, 2026
07:20
Studies on the Anti-Inflammatory Effect of Xiaoyao Pills in The Treatment of Postmenopausal Osteoporosis in Mice
Published on: August 23, 2024
Osteoporosis: New-Generation Drugs.
1Department II Rheumatology/Osteology and Gastroenterology, KH Barmherzige Schwestern (St. Vincent Hospital), Medical University Vienna, Austria.
Breast Care (Basel, Switzerland)
|July 23, 2011
Summary
Denosumab, a monoclonal antibody targeting RANKL, effectively treats postmenopausal osteoporosis by suppressing bone resorption. Clinical trials show it increases bone mineral density and reduces fracture risk, offering a favorable safety profile.
Area of Science:
- Bone biology and pharmacology
- Monoclonal antibody therapeutics
- Osteoporosis treatment
Background:
- Advances in bone pathophysiology led to the development of targeted therapies.
- Receptor activator of nuclear factor kappa-B ligand (RANKL) plays a crucial role in osteoclast formation and activity.
- Denosumab is a fully human monoclonal antibody inhibiting the RANKL/RANK interaction.
Purpose of the Study:
- To evaluate the efficacy and safety of denosumab for treating postmenopausal osteoporosis (PMO).
- To assess denosumab's role in treatment-induced bone loss for cancer patients.
- To compare denosumab with existing osteoporosis treatments.
Main Methods:
- Clinical trials involving postmenopausal osteoporosis patients.
- Assessment of bone mineral density (BMD) and bone turnover markers.
- Evaluation of fracture risk reduction and adverse event profiles.
Main Results:
- Denosumab demonstrated significant increases in BMD across skeletal sites.
- Reductions in bone turnover markers and fracture incidence were observed.
- Head-to-head studies indicated denosumab's superiority over alendronate in increasing BMD.
- Favorable risk-benefit profile with comparable rates of adverse events to controls.
Conclusions:
- Denosumab is approved for postmenopausal osteoporosis and treatment-induced bone loss.
- The drug effectively increases BMD and reduces fracture risk in PMO patients.
- Subcutaneous administration (60 mg twice yearly) offers patient and physician convenience.
Related Concept Videos
01:29Bone Disorders
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
01:40Bone Remodeling
Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
01:31Osteoclasts in Bone Remodeling
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during bone...
01:26FDA Approved Drugs: Changes to Approved Drugs
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
01:15Drug Dosing: Geriatric Patients
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...